On March 4, 2019 March 04, 2019 Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, reported it will present a poster on the performance of its lead investigational drug, lasofoxifene, at ENDO 2019, the annual meeting of the Endocrine Society (Press release, Sermonix Pharmaceuticals, MAR 4, 2019, View Source [SID1234534381]). The abstract, "Lasofoxifene Achieves Potent Anti-Tumor Activity in Y537S ESR1 Hormone-Resistant Breast Cancer Cells by Saturating ERα," will be presented Sunday, March 24, in a 1-3 p.m. poster session at the Ernest N. Morial Convention Center in New Orleans.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sermonix, which is currently enrolling patients in a Phase 2 clinical study of lasofoxifene, collaborated with researchers at the University of Chicago on the poster to be presented at ENDO 2019.
"Our laboratory has been looking for potent, effective inhibitors of tumor progression and metastases, especially in hormone-resistant tumors, so we were excited to observe the significant efficacy of lasofoxifene," said Dr. Geoffrey Greene, Ph.D., chair of the Ben May Department for Cancer Research at the University of Chicago, and the poster’s senior author. "We look forward to detailing our findings at ENDO 2019."
One of the primary goals of collaborating with the University of Chicago was to support Sermonix’s preclinical program – supplementing lasofoxifene’s well-characterized pharmacology – with further study of recently discovered activity in metastatic breast cancers harboring estrogen receptor mutations, according to Barry Komm, Ph.D., Sermonix chief scientific officer.
"This new data collection from Dr. Greene and team is helping us achieve that goal, continuing our momentum toward developing lasofoxifene as a potential novel precision medicine for women diagnosed with treatment-resistant metastatic breast cancer," said Komm.
The U.S. Food and Drug Administration in December accepted Sermonix’s Investigational New Drug application, indicating the company could proceed directly to a Phase 2 clinical study of lasofoxifene. The open-label, randomized, multi-center study will evaluate the activity of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.